Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype by E V Karabina, L G Zhukova

Get full text

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice by E. V. Karabina, L. N. Lubchenko, M. M. Davydov

Get full text

The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer by E V Karabina, L N Lubchenko, A N Garunov

Get full text

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES by E. V. Karabina, L. N. Lubchenko, M. M. Davydov

Get full text

Off-Label Drug Use in Oncology by E. V. Karabina, D. D. Sakaeva, O. N. Lipatov

Get full text

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia by L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova

Get full text

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study by E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova

Get full text

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study by M.   Yu. Fedyanin, L.  Yu.  Vladimirova, V.  A.  Chubenko, L.   A. Zagorskaya, A.  V.  Belyaeva, O.  L.  Fakhrutdinova, S.  A.  Belukhin, A.   S. Zhabina, L.   V. Khalikova, L.  V.  Bolotina, R.   V. Orlova, F.  V.  Moiseenko, G.   Z. Mukhametshina, A.  I.  Khasanova, A.  V.  Belonogov, Kh.  S.  Musaeva, O.  Yu.  Novikova, I.  Yu.  Stradaeva, I.  L.  Popova, S.  P.  Erdniev, A.  K.  Ivanova, A.  V.  Androsova, P.  S.  Feoktistova, E.  S.  Kuzmina, E.   V. Karabina, O.  V.  Nekrasova, O.  V.  Sekhina, A.   A. Mishchenko, L.  A.  Mukova, B.  Kh.  Kertiev, G.  I.  Kosar, S.   N. Osodoeva, A.  I.  Kats, R.  R.  Malina, M.  A.  Lyadova, A.  A.  Tryakin, S.  A.  Tyulandin

Get full text

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer by M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin

Get full text